MedImmune and Abpro team on Ang2-VEGF targeting antibody

By Gareth Macdonald

- Last updated on GMT

AstrzaZeneca’s MedImmune has set up a spin-out company with Abpro that will develop a bi-specific antibody therapeutic.

The joint venture – AbMed - will focus on an antibody that targets angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).

The firm will develop the molecule for a number of undisclosed therapeutic areas. 

AbMed – which will operate as a subsidiary of Abpro – will hold development and commercialization rights to the programme, while MedImmune will receive development, regulatory and sales milestones and royalties.

An Abpro Spokesman told us the firm "will be leveraging its DiversImmune platform to bring the antibody to clinical trials. Abpro has an extensive network of manufacturing partners to prepare for clinical trials. We are committed to our partners in the US to carry this out​."

He added that: "Once our clinical trials are completed, we will make this therapy widely available to treat patients and improve their quality of life​."

This was echoed by Rebecca Einhorn from MedImmune who told us "AbPro will have day-to-day leadership in overseeing the new company, AbMed, and AbPro’s core technology platform, DiversImmune, will be used to further refine the antibody​."

She declined to disclose the therapeutic areas that AbMed will focus on.

Related news

Show more

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Riding the mRNA Highway

Riding the mRNA Highway

Content provided by Thermo Fisher Scientific - Biosciences | 15-May-2023 | White Paper

Learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications.

Related suppliers

Follow us


View more